drug

gedatolisib

1 story · latest Sep 30, 2026

Status: FDA approved Jul 2026 · NDA219908
Brand: Revtorpyk

Relationships

Developed by Celcuity Inc

Timeline

Celcuity launches REVTORPYK for HR+/HER2- advanced breast cancer

Sep 30Regulatory decisionCelcuity Inc gedatolisib

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.